India's Marksans Pharma rises on USFDA nod for acidity drug

Marksans Pharma

10/03/2023 07:47

** Shares of Marksans Pharma  MARK.NS  rise as much as 2.22%
to 69.15 rupees
    ** Rise comes after pharmaceutical formulations maker
receives final approval from USFDA for its drug to treat acidity
    ** U.S. drug regulator gave its final approval for
Famotidine tablets, 10 mg and 20 mg, for over-the-counter use
    ** Tablets used as acid reducers to treat reduction of
stomach acid, indigestion, and occasional heartburn
    ** Approval to fill an important therapy gap in antacids
market due to the recent withdrawal of Ranitidine, says co's
Managing Director Mark Saldanha
    ** Trading volume is over 1.48 mln shares as of 1:10 p.m.
IST, 0.8x the 30-day avg - Refinitiv data

 (Reporting by Bharath Rajeswaran in Bengaluru)
 ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463))